Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
J Pharmacol Exp Ther ; 368(2): 199-207, 2019 02.
Artigo em Inglês | MEDLINE | ID: mdl-30523062

RESUMO

Translating chemogenetic techniques from nonhuman primates to potential clinical applications has been complicated in part due to in vivo conversion of the chemogenetic actuator, clozapine N-oxide (CNO), to its pharmacologically active parent compound, clozapine, a ligand with known side effects, including five boxed warnings from the Food and Drug Administration. Additionally, the limited solubility of CNO requires high concentrations of potentially toxic detergents such as dimethylsulfoxide (DMSO). To address these concerns, pharmacokinetic profiling of commercially available CNO in DMSO (CNO-DMSO, 10% v/v DMSO in saline) and a water-soluble salt preparation (CNO-HCl, saline) was conducted in rhesus macaques. A time course of blood plasma and cerebrospinal fluid (CSF) concentrations of CNO and clozapine was conducted (30-240 minutes post-administration) following a range of doses (3-10 mg/kg, i.m. and/or i.v.) of CNO-DMSO or CNO-HCl. CNO-HCl resulted in 6- to 7-fold higher plasma concentrations of CNO compared to CNO-DMSO, and relatively less clozapine (3%-5% clozapine/CNO in the CNO-DMSO group and 0.5%-1.5% clozapine/CNO in the CNO-HCl group). Both groups had large between-subjects variability, pointing to the necessity of performing individual CNO pharmacokinetic studies prior to further experimentation. The ratio of CNO measured in the CSF was between 2% and 6% of that measured in the plasma and did not differ across drug preparation, indicating that CSF concentrations may be approximated from plasma samples. In conclusion, CNO-HCl demonstrated improved bioavailability compared with CNO-DMSO with less conversion to clozapine. Further investigation is needed to determine if brain concentrations of clozapine following CNO-HCl administration are pharmacologically active at off-target monoaminergic receptor systems in the primate brain.


Assuntos
Antipsicóticos/farmacocinética , Clozapina/análogos & derivados , Ácido Clorídrico/farmacocinética , Animais , Antipsicóticos/sangue , Antipsicóticos/líquido cefalorraquidiano , Clozapina/sangue , Clozapina/líquido cefalorraquidiano , Clozapina/farmacocinética , Feminino , Ácido Clorídrico/sangue , Ácido Clorídrico/líquido cefalorraquidiano , Macaca mulatta , Masculino
2.
AAPS PharmSciTech ; 12(2): 496-506, 2011 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-21479748

RESUMO

Upon topical administration, a high penetration rate of antifungal drug into the infected site is desirable to reduce treatment length and systemic side effects which occur especially after a prolonged peroral administration. Thermogelling formulations composed of poloxamer 407, medium chain triglycerides, isopropyl alcohol, dimethyl isosorbide, and water for topical application were developed, and a lipophilic drug terbinafine HCl (TBF) was incorporated. Previously, a remarkable high permeation rate of a hydrophilic drug 5-aminolevulinic acid from this vehicle was evident compared to different creams from German Pharmacopoeia. By varying the composition of vehicle constituents, a broad range of consistencies and appearances was obtained. Up to 4% TBF could be solubilized in the vehicle. TBF fluxes at steady state across human stratum corneum from these formulations were higher than those from the German Pharmacopoeia Basiscreme Deutscher Arzneimittel Codex and a marketed product at similar concentration of 1%. TBF fluxes increased along with a higher content of TBF in the formulation. The amount of TBF retained in stratum corneum was higher compared to those from both standards of comparison (p < 0.01). The thermodynamic activity of TBF in the thermogelling formulation was lower compared to those in other formulations. Therefore, the nature of the vehicle and its interaction with TBF are suggested to play a significant role in explaining higher fluxes along with higher TBF content. Differential scanning calorimetry measurements revealed comparable T2 and T3 endothermic shifts from all examined formulations suggesting equal influences to the skin lipids.


Assuntos
Química Farmacêutica/métodos , Epiderme/metabolismo , Ácido Clorídrico/farmacocinética , Naftalenos/farmacocinética , Poloxâmero/farmacocinética , Administração Tópica , Adulto , Química Farmacêutica/normas , Epiderme/efeitos dos fármacos , Feminino , Géis/normas , Humanos , Ácido Clorídrico/administração & dosagem , Ácido Clorídrico/química , Pessoa de Meia-Idade , Naftalenos/administração & dosagem , Naftalenos/química , Permeabilidade/efeitos dos fármacos , Poloxâmero/administração & dosagem , Poloxâmero/química , Terbinafina
3.
Braz. j. pharm. sci ; 47(4): 899-906, Oct.-Dec. 2011. ilus, graf, tab
Artigo em Inglês | LILACS | ID: lil-618083

RESUMO

The present study describes the development and validation of a dissolution method for carvedilol compression-coated tablets. Dissolution test was performed using a TDT-06T dissolution apparatus. Based on the physiological conditions of the body, 0.1N hydrochloric acid was used as dissolution medium and release was monitored for 2 hours to verify the immediate release pattern of the drug in acidic pH, followed by pH 6.8 in citric-phosphate buffer for 22 hours, to simulate a sustained release pattern in the intestine. Influences of rotation speed and surfactant concentration in medium were evaluated. Samples were analysed by validated UV visible spectrophotometric method at 286 nm. 1 percent sodium lauryl sulphate (SLS) was found to be optimum for improving carvedilol solubility in pH 6.8 citric-phosphate buffer. Analysis of variance showed no significant difference between the results obtained at 50 and 100 rpm. The discriminating dissolution method was successfully developed for carvedilol compression-coated tablets. The conditions that allowed dissolution determination were USP type I apparatus at 100 rpm, containing 1000 ml of 0.1N HCl for 2 hours, followed by pH 6.8 citric-phosphate buffer with 1 percent SLS for 22 hours at 37.0 ± 0.5 ºC. Samples were analysed by UV spectrophotometric method and validated as per ICH guidelines.


O presente estudo descreve o desenvolvimento e a validação de método de dissolução para comprimidos revestidos de carvedilol. O teste de dissolução foi efetuado utilizando-se o aparelho para dissolução TDT-06T. Com base nas condições fisiológicas do organismo, utilizou-se ácido clorídrico 0,1 N como meio de dissolução e a liberação foi monitorada por 2 horas para se verificar o padrão de liberação imediata do fármaco em condições de pH baixo, seguidas por pH 6,8 em tampão cítrico-fosfato por 22 horas, para simular o padrão de liberação controlada no intestino. Avaliou-se a influência da velocidade de rotação e a concentração de tensoativo no meio. As amostras foram analisadas por método espectrofotométrico UV-visível validado, em 286 nm. O laurilsulfato sódico a 1 por cento (SLS) mostrou-se ótimo para aumentar a solubilidade do carvedilol em pH 6,8 em tampão cítrico-fosfato. A análise da variância não mostrou diferença significativa entre os resultados obtidos a 50 e a 100 rpm. O método da dissolução discriminante foi desenvolvido com sucesso para os comprimidos revestidos de carvedilol. As condições que permitiram a determinação da dissolução foram: aparelho USP tipo I a 100 rpm, contendo 1000 mL de HCL 0,1 N por 2 horas, seguido de pH 6,8 com tampão cítrico-fosfato, com 1 por cento de SLS por 22 horas a 37,0 ± 0,5 ºC. Amostras foram analisadas por método espectrofotométrico e validadas pelas normas ICH.


Assuntos
Comprimidos com Revestimento Entérico/análise , Estudo de Validação , Dissolução/métodos , Dodecilsulfato de Sódio/farmacocinética , Ácido Clorídrico/farmacocinética
4.
Braz. j. pharm. sci ; 45(4): 829-840, Oct.-Dec. 2009. tab, ilus
Artigo em Inglês | LILACS | ID: lil-543679

RESUMO

The present study investigated a novel extended release system of promethazine hydrochloride (PHC) with acrylic polymers Eudragit RL100 and Eudragit S100 in different weight ratios (1:1 and 1: 5), and in combination (0.5+1.5), using freeze-drying and spray-drying techniques. Solid dispersions were characterized by Fourier-transformed infrared spectroscopy (FT-IR), differential scanning calorimetry (DSC), Powder X-ray diffractometry (PXRD), Nuclear magnetic resonance (NMR), Scanning electron microscopy (SEM), as well as solubility and in vitro dissolution studies in 0.1 N HCl (pH 1.2), double-distilled water and phosphate buffer (pH 7.4). Adsorption tests from drug solution to solid polymers were also performed. A selected solid dispersion system was developed into capsule dosage form and evaluated for in vitro dissolution studies. The progressive disappearance of drug peaks in thermotropic profiles of spray-dried dispersions were related to increasing amount of polymers, while SEM studies suggested homogenous dispersion of drug in polymer. Eudragit RL100 had a greater adsorptive capacity than Eudragit S100, and thus its combination in (0.5+1.5) for S100 and RL 100 exhibited a higher dissolution rate with 97.14 percent drug release for twelve hours. Among different formulations, capsules prepared by combination of acrylic polymers using spray-drying (1:0.5 + 1.5) displayed extended release of drug for twelve hours with 96.87 percent release followed by zero order kinetics (r²= 0.9986).


O presente trabalho compreendeu estudo de um novo sistema de liberação prolongada de cloridrato de prometazina (PHC) com polímeros acrílicos Eudragit RL100 e Eudragit S100 em diferentes proporções em massa (1:1 e 1:5) e em combinação (0,5+1,5), utilizando técnicas de liofilização e de secagem por aspersão As dispersões sólidas foram caracterizadas por espectrofotometria no infravermelho por transformada de Fourier (FT-IR), calorimetria diferencial de varredura (DSC), difratometria de raios X (PXRD), Ressonância Magnética Nuclear (RMN), microscopia eletrônica de varredura (SEM) e, também, por estudos de solubilidade e de dissolução in vitro em HCl 0,1 N (pH 1,2), água bidestilada e tampão fosfato (pH 7,4). Realizaram-se, também, testes de adsorção da solução do fármaco nos polímeros sólidos. Desenvolveu-se sistema de dispersão sólida exclusiva dentro das cápsulas, que foi avaliado por meio de estudos de dissolução in vitro. Relacionou-se o desaparecimento progressivo de picos do fármaco em perfis termotrópicos de dispersões secas por spray à quantidade aumentada de polímero, enquanto os estudos de SEM sugeriram dispersão homogênea do fármaco no polímero. O Eudragit RL100 apresentou maior capacidade de adsorção do que o Eudragit S100 e, dessa forma, a combinação de (0,5+1,5) para S100 e para RL100 mostrou taxa de dissolução maior, com liberação de 94,17 por cento de fármaco em 12 horas. Entre as várias formulações, as cápsulas preparadas pela combinação de polímeros acrílicos utilizando secagem por aspersão (0,5+1,5) apresentou liberação prolongada do fármaco em 12 horas, com 96,78 por cento de liberação, seguindo cinética de ordem zero (r² = 0,9986).


Assuntos
Ácido Clorídrico/farmacocinética , Química Farmacêutica , Preparações de Ação Retardada , Polímeros/farmacocinética , Fenômenos de Química Orgânica , Prometazina/farmacocinética , Avaliação de Medicamentos , Liofilização , Preparações Farmacêuticas
5.
Exp Dermatol ; 17(10): 813-20, 2008 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-18380780

RESUMO

Topical photodynamic therapy with 5-aminolevulinic acid (5-ALA) is a newly established treatment modality for epithelial skin cancer. Skin distribution of different 20% 5-ALA formulations was investigated by detection of protoporphyrin IX (PpIX) using an ex vivo porcine skin model. Fluorescence of PpIX was first detectable at 2 h after application of a 5-ALA/HCl-alcohol solution, followed by a 5-ALA gel +/- 40% DMSO > 5-ALA lipophilic ointment > 5-ALA hydrophilic ointment at 4 h after application. Intensity of PpIX was 10-fold higher after 5-ALA/HCl-alcohol application in contrast to 5-ALA hydrophilic ointment. Maxima of PpIX fluorescence were measured between 18 and 24 h after application. PpIX accumulation induced by 5-ALA within the lower parts of the epidermis was increased in order of 5-ALA hydrophilic ointment < 5-ALA lipophilic ointment < 5-ALA gel w/o DMSO < 5-ALA gel with DMSO < 5-ALA/HCl-alcohol. Illumination of skin incubated with different 5-ALA formulations led to a marked increase of apoptotic cells in the epidermis depending on the penetration depth of the 5-ALA formulations. A formulation containing short chain alcohols have been observed to increase the permeation and distribution of 5-ALA. PpIX fluorescence was detected earlier yielding to photodynamic effective amounts of PpIX in the epidermis as compared with all other 5-ALA formulations used. These data emphasizes the potential of investigating properties of new formulations using such a full thickness porcine skin model.


Assuntos
Álcoois/farmacocinética , Ácido Aminolevulínico/farmacocinética , Ácido Clorídrico/farmacocinética , Fotoquimioterapia , Pele/efeitos dos fármacos , Álcoois/toxicidade , Ácido Aminolevulínico/toxicidade , Animais , Feminino , Ácido Clorídrico/toxicidade , Microscopia de Fluorescência , Modelos Animais , Fármacos Fotossensibilizantes/farmacocinética , Fármacos Fotossensibilizantes/toxicidade , Protoporfirinas/metabolismo , Pele/metabolismo , Fita Cirúrgica , Sus scrofa
6.
Int J Pharm ; 252(1-2): 99-109, 2003 Feb 18.
Artigo em Inglês | MEDLINE | ID: mdl-12550785

RESUMO

In this study, the microspheres containing verapamil hydrochloride (VRP) were prepared with Eudragit RS 100 by solvent evaporation method. In the solvent evaporation method one of the parameters which affect to the formation and properties of the microspheres is the variations of drug/polymer ratios. The aim of our study is to examine the effects of this parameter on the VRP loaded microspheres. To achieve this purpose, only drug/polymer ratio was altered while the other formulation parameters were kept constant and percentage yield value, incorporation efficiency, particle size and distribution of the microspheres were analyzed and micrographs of the microspheres were taken to determine the effects of the increase in the polymer amount of formulations. All the dispersed phase viscosities were evaluated by comparing them with the variations in particle size and distribution of the microspheres. In vitro dissolution tests were done by using dissolution media with three different pH in sequence as half-change method with flow through cell and the effect of the variation in polymer ratio on drug dissolution was evaluated according to dissolution test results. As a result of our study, it is thought that the variation in drug/polymer ratios might have an influence on the physical characteristics of the microspheres and the increasing amount of polymer might be result in decreased drug dissolve.


Assuntos
Ácido Clorídrico/farmacocinética , Polímeros/farmacocinética , Verapamil/farmacocinética , Química Farmacêutica , Ácido Clorídrico/química , Microesferas , Polímeros/química , Solubilidade , Verapamil/química
7.
Aliment Pharmacol Ther ; 15(9): 1385-8, 2001 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-11552909

RESUMO

BACKGROUND: Cisapride has been shown to have not only prokinetic effects, but also salivary stimulating effects. Both of these mechanisms play an important role in the acid clearance of the oesophagus. AIM: To access the efficacy of cisapride in facilitating acid clearance in patients with symptomatic gastro-oesophageal reflux disease. METHODS: Fifteen older adults and 15 younger adults with symptomatic gastro-oesophageal reflux disease completed the study. The acid clearance test was accomplished by infusing 15 mL of 0.1 N HCl into the distal oesophagus, and the number of swallows was determined to achieve an oesophageal pH of 4.0. This was accomplished under baseline conditions and salivary stimulation with a peppermint lozenge. After 1 week of treatment with cisapride (10 mg, q.d.s.), the acid clearance test was repeated. RESULTS: The lozenge produced a significant decrease in the number of swallows compared to baseline in both groups (P < 0.01). There was a significant decrease in the number of swallows after the treatment with cisapride compared to baseline in both groups (P < 0.01). No significant difference was found in the number of swallows when comparing cisapride with lozenge. CONCLUSIONS: Cholinergic stimulation of salivation is an effective means of facilitating oesophageal acid clearance. Drugs, such as 5 hydroxytriptamine (5-HT)4-receptor agonists, should be considered as potentially important compounds in the treatment of gastro-oesophageal reflux disease.


Assuntos
Envelhecimento , Antiulcerosos/uso terapêutico , Cisaprida/uso terapêutico , Refluxo Gastroesofágico/tratamento farmacológico , Ácido Clorídrico/farmacocinética , Salivação/efeitos dos fármacos , Idoso , Deglutição/efeitos dos fármacos , Humanos , Concentração de Íons de Hidrogênio/efeitos dos fármacos , Taxa de Depuração Metabólica , Pessoa de Meia-Idade
8.
Eur J Gastroenterol Hepatol ; 8(3): 205-9, 1996 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-8724018

RESUMO

OBJECTIVE: To test the effect of body position on oesophageal acid clearance time in patients with systemic sclerosis. DESIGN AND METHODS: Fifteen consecutive patients with systemic sclerosis and six healthy subjects underwent oesophageal manometry and an acid clearance test in three body positions (supine, recumbent at 30 degrees and seated at 90 degrees) in randomized order. RESULTS: In healthy subjects the body position did not affect acid clearance time, whereas in patients the oesophagus cleared mainly by gravity. In patients the acid clearance time was significantly longer in the supine than in the seated position (P < 0.05). Nine patients did not have a detectable peristaltic wave in the distal oesophagus. In the other six oesophageal peristalsis was still detectable but contractions had reduced amplitude and often had double and triple peaks; also in this subgroup the acid clearance time recorded in the supine position was prolonged. CONCLUSIONS: In systemic sclerosis gravity plays a major role in oesophageal acid clearance time. The finding of delayed acid clearance in a supine patient may suggest initial oesophageal involvement in the disease.


Assuntos
Esôfago/fisiopatologia , Ácido Clorídrico/farmacocinética , Postura , Escleroderma Sistêmico/fisiopatologia , Adolescente , Adulto , Idoso , Deglutição , Transtornos de Deglutição/fisiopatologia , Transtornos da Motilidade Esofágica/fisiopatologia , Esofagite/fisiopatologia , Junção Esofagogástrica/fisiopatologia , Esôfago/metabolismo , Feminino , Refluxo Gastroesofágico/fisiopatologia , Gravitação , Azia/fisiopatologia , Humanos , Ácido Clorídrico/administração & dosagem , Concentração de Íons de Hidrogênio , Intubação , Masculino , Manometria , Pessoa de Meia-Idade , Peristaltismo , Decúbito Dorsal , Fatores de Tempo
9.
Acta Pol Pharm ; 48(3-4): 27-31, 1991.
Artigo em Inglês | MEDLINE | ID: mdl-1669540

RESUMO

The rate of HCl neutralization by dihydroxyaluminum sodium carbonate (DHASC), hydrotalcite (HT) and dihydroxyaluminum aminoacetate (DHAAA) in the presence of different amount of pepsin (PP) has been studied at constant pH = 3.0. The results can be explained using Weibull distribution function by comparing the kinetical parameters with and without the substance added and as a function of their concentration. Some aspects of mechanisms of inhibition or acceleration of acid neutralization of DHASC, HT and DHAAA by PP are also discussed.


Assuntos
Antiácidos/química , Antiácidos/farmacocinética , Ácido Clorídrico/química , Pepsina A/farmacologia , Hidróxido de Alumínio/química , Hidróxido de Alumínio/farmacocinética , Glicina/análogos & derivados , Glicina/química , Glicina/farmacocinética , Ácido Clorídrico/farmacocinética , Concentração de Íons de Hidrogênio , Cinética , Hidróxido de Magnésio/química , Hidróxido de Magnésio/farmacocinética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...